English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 2 June 2023, 12:20 JST
Share:
    

Source: Eisai
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting

TOKYO, June 2, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States.

Major poster presentations include new data about the effects of lemborexant on obstructive sleep apnea (poster numbers: #298, 299 and 300).

Eisai considers neurology, including insomnia, a therapeutic area of focus. Eisai strives to create innovative products as soon as possible in therapeutic areas with high unmet medical needs, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

About Lemborexant (product name: DAYVIGO)

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 15 countries including Japan, the United States, Canada, Australia and countries in Asia.

For more information, visit www.eisai.com/news/2023/news202340.html.

Media Inquiries:

Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Inc. (U.S.)
TEL: +551-305-0050
Christopher_Vancheri@eisai.com

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Tuesday, 28 May 2024, 15:19 JST
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
Thursday, 23 May 2024, 18:07 JST
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
Wednesday, 22 May 2024, 12:55 JST
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
Wednesday, 15 May 2024, 11:19 JST
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Monday, 13 May 2024, 17:06 JST
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575